EBMT Activity Survey Teams Patients Transplants

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.

Advertisements

Hematopoietic stem cell transplantation

Module 1 Haematopoietic stem cell transplantation.

CLINICAL CODING FOR BM & PBSC TRANSPLANT PROCEDURES Dr Kim Orchard – Transplant Director Carol Hurlock – Data Manager Wessex Blood and Marrow Transplantation.

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.

Allogeneic Stem Cell Transplantation: The Journey

Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.

The Middle East The The Arab World.

Kelsey Cramer. MEET MY AUNT DONATING BONE MARROW.

What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.

CHAPTER 1 BLOOD AND MARROW TRANSPLANTATION Editors: Dr Alan Teh Kee Hean Prof Dr Chan Lee Lee Expert Panel: Dr Alan Teh Kee Hean (co-chairperson) Prof.

Bone marrow Transplant in Paediatric Haematology

Jordan Morocco Saudi Arabia Algeria Yemen Tunisia Oman Libya

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

What to label… Middle East pg. 164, Countries: Turkey, Syria, Lebanon, Israel, West Bank*, Gaza*, Egypt, Jordan, Saudi Arabia, Yemen, Oman, United.

(A) the hematopoietic stem cell transplanted (HSCT) recipients only (B) both autologous and allogeneic transplanted recipients (C) both solid organ and.

Bone Marrow Donation. What is Bone marrow?  flexible spongy tissue in the interior of bones such as your hip and thigh.  constitutes 4% of the total.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation, Year New transplant patients Deaths

Dr. Kasi Viswanathan, Head Dept. Of Haematology & Bone marrow transplantation Dept. Of Pediatric Oncology, Meenakshi Mission Hospital & Research Centre,

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

University Hamburg Medical Center Dept of Stem Cell Transplantation

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

Source: Freedom House, Freedom in the World 2006

العمل، النمو والنوع الاجتماعي والحكم في الوطن العربي

Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Miguel-Angel Perales MD

EBMT Activity Survey Teams 39,313 Patients 43,636 Transplants

EBMT Activity Survey Teams Patients Transplants

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases: Unrelated Cord Blood and Haploidentical Family Donors Mitchell S. Cairo,

What to label… Middle East North Africa

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and.

Figure 5 Number of AHSCT procedures for

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

Cord blood transplantation and stem cell regenerative potential

Figure 2 Components of each transplantation platform

Letermovir(Prevymis™) Guidelines for Inpatient Use

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Table 1.1.1: Stock and Flow of Blood and Marrow Transplantation,

LONG TERM Outcomes of Pediatric Patients with Malignant and NON-Malignant Disorders Receiving Α/Β T-CELL Depleted HLA-Haploidentical Hematopoietic STEM.

Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance Allison M. Bock, Qing.

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Twenty Years of Unrelated Donor Bone Marrow Transplantation for Pediatric Acute Leukemia Facilitated by the National Marrow Donor Program Margaret L.

Biology of Blood and Marrow Transplantation

Elucidating a Lipidomic and Metabolomic Signature of Gvhd in Recipients of Allogeneic Stem Cell Transplants Daniel Contaifer, Catherine H. Roberts, Urszula.

Kasiani C. Myers, Stella M. Davies

Cutaneous Complications in Hematopoietic Cell Transplant Recipients: Impact of Biopsy on Patient Management Oana Paun, Tycel Phillips, Pingfu Fu, Roberto.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review

Allogeneic Stem Cell Transplantation for Aplastic Anemia

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.

Aplastic Anemia: Pathophysiology and Treatment

Hematopoietic Stem Cell Transplantation Dr . Ghassemi A Associate professor of pediatric Hematologist Oncologist & stem cell transplantation.

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Bridge to transplant following Bv+Bs regimen.

Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R

Eliane Gluckman Experimental Hematology

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based.

Likelihood of finding unrelated donor or cord blood

The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.

Likelihood of finding unrelated donor or cord blood

Mary Eapen Biology of Blood and Marrow Transplantation

How I treat acquired aplastic anemia

Presentation transcript:

EBMT Activity Survey 2015 655 Teams 37 626 Patients 42 171 Transplants 48 Countries For internal use only. For any other use, please contact Helen Baldomero for permission: helen.baldomero@usb.ch

EBMT Activity Survey in 2015: Patient and transplant numbers Allogeneic HSCT Autologous Total 1st allo/1st auto HSCT Additional HSCT TOTAL Teams: 655 (of 687) Countries reporting: 48 16 030 1 272 17 302 21 596 3 273 24 869 37 626 4 545 42 171 Indication Baldomero: Transplant Activity Survey Dec 2016

EBMT Activity Survey in 2015: Donor type and stem cell source: all transplants PBSC HLA-id HLA-non id Unrelated Syngeneic Allogeneic Autologous 1 489 827 1 426 n.a. 3 742 98 5 888 2 386 9 001 27 17 302 24 869 Total 4 359 1 554 7 164 13 077 24 770 Donor type Stem Cell Source Cord 40 5 411 456 1 Baldomero: Transplant Activity Survey Dec 2016

EBMT Activity Survey 2015: Main indications Allogeneic 1st HSCT Baldomero: Transplant Activity Survey Dec 2016 EBMT Activity Survey 2015: Main indications Allogeneic 1st HSCT Autologous Total Leukemia Lymphoma Plasma Cell disorder Solid tumor Non-malignant disorders Bone marrow failure Other Total 1st Transplants 11 743 1 574 567 38 1 985 827 123 16 030 539 8 143 11 187 1 478 223 26 21 596 12 282 9 717 11 754 1 516 2 208 149 37 626 Indication

Allogeneic HSCT in Europe 2015 1st HSCT JR. Passweg et al BMT (2017) March 13 Epub Baldomero: Transplant Activity Survey Dec 2016

Autologous HSCT in Europe 2015 1st HSCT JR. Passweg et al BMT (2017) March 13 Epub Baldomero: Transplant Activity Survey Dec 2016

HSCT Activity in Europe 1990-2015: Baldomero: Transplant Activity Survey Dec 2016 HSCT Activity in Europe 1990-2015: Transplant type 1st HSCT

HSCT Activity in Europe 1990-2015: Baldomero: Transplant Activity Survey Dec 2016 HSCT Activity in Europe 1990-2015: Donor origin: 1st HSCT

HSCT Activity in Europe 1990-2015: Baldomero: Transplant Activity Survey Dec 2016 HSCT Activity in Europe 1990-2015: Main Indications: allogeneic

HSCT Activity in Europe 1990-2015: Main Indications: autologous Baldomero: Transplant Activity Survey Dec 2016

HSCT - rates in Europe 2015 N. allogeneic transplants per 10 million population 0 or no report 1 - 100 101 - 150 151 – 200 201 – 300 > 300 Nigeria Algeria, Iran, Jordan, Kazakhstan, Lebanon, South Africa, Tunisia Saudi Arabia Israel Baldomero: Transplant Activity Survey Dec 2016

HSCT - rates in Europe 2015 N. autologous transplants per 10 million population 0 or no report 1 - 100 101 - 200 201 – 300 301 – 400 > 400 Nigeria Algeria, Iran, Jordan, Kazakhstan, Lebanon, Saudi Arabia, South Africa, Tunisia Israel Baldomero: Transplant Activity Survey Dec 2016